China Pharma Holdings, Inc. — Q1 2016 Form 10-Q
Reporting period: Three months ended March 31, 2016; unaudited consolidated financial statements. China Pharma Holdings manufactures and markets generic and branded pharmaceuticals and biochemical products in China, primarily to hospitals and private retailers.
Financial performance
| Metric | Q1 2016 | Q1 2015 / comparison |
|---|---|---|
| Revenue | $3.64 million | $5.69 million; down 36.1% |
| Gross profit / margin | $0.64 million / 17.6% | $1.06 million / 18.6% |
| Operating loss | $1.32 million | $3.76 million |
| Net loss | $1.55 million; $0.04 per share | $4.07 million; $0.09 per share |
| Operating cash flow | $1.30 million provided | $2,239 used |
| Cash and cash equivalents | $7.26 million at March 31 | $6.25 million at December 31, 2015 |
| Total assets / liabilities | $97.03 million / $25.46 million | At March 31, 2016 |
| Bank debt | Approximately $16.75 million | $4.65 million short-term notes and $12.10 million construction facility |
Current assets were $25.12 million and current liabilities $14.06 million, implying working capital of approximately $11.06 million and a current ratio of about 1.8. Cash is held in the PRC subsidiary and management considers it indefinitely reinvested; it is not expected to be available for dividends or parent-company payments. Cash generated from operations was supported by working-capital movements, including inventory reductions and increases in payables and customer advances. Investing cash use was $39,248 and financing cash use was $305,835.
Changes and operating drivers
- Revenue declined chiefly because provincial tenders missed before new GMP certification reduced market share, with the sales impact continuing into 2016, and because healthcare cost controls pressured sales.
- Anti-Viro/Infection & Respiratory revenue fell 38% to $2.53 million, primarily due to lower Cefaclor dispersible tablet sales. “Other” category sales fell 61% to $0.31 million; digestive-disease sales rose 36% to $0.19 million.
- Gross margin decreased to 17.6% from 18.6%, which management attributed mainly to lower selling prices on certain products. Cost of revenue was 84.4% of revenue versus 77.9%.
- Net loss narrowed substantially, mainly because bad-debt expense fell to $0.58 million from $3.20 million. Selling expense remained about $0.97 million, increasing as a share of revenue to 26.6% from 17.4%.
Liquidity, outlook, and risks
Management said operating cash flow should cover working-capital needs and anticipated capital expenditures, including formula acquisitions and remaining GMP-related spending, for the next 12 months. This is not a quantified earnings or revenue forecast. Management cautioned that a shortfall against its operating plan could require additional financing or spending reductions; financing may not be available on acceptable terms.
- The $4.65 million short-term credit line is due in two installments in September and October 2016; the filing states the company has no remaining availability under the line. The construction loan carries a 5.94% rate as of the disclosed adjustment and has scheduled principal payments, including $1.55 million due within 12 months.
- Receivable collectability is a key risk: $5.8 million was past due by more than 90 days, and 73.8% of receivables were in the over-720-day aging category under the company’s aging disclosure. The allowance for doubtful accounts was $29.6 million; the company reported $16.85 million of receivables more than one year old that it believes are collectible.
- PRC healthcare-cost controls, product-price pressure, intense pharmaceutical competition, and further CFDA review requirements may constrain sales and product development. New generic products must undergo consistency evaluation, which management said could extend approval timelines. Formula approval processes typically take two to five years.
- Approximately $4.8 million is committed to laboratories and others over about four years, contingent on completion of contract phases for CFDA approvals. No formula approvals were obtained in Q1 2016; management reported no known failures to date but gave no assurance of future approval.
- All revenue is denominated in RMB. PRC foreign-exchange conversion and remittance restrictions may limit transfers to the U.S. parent. The filing also identifies PRC political, economic, legal, currency, and bank-deposit risks.
The company reported no off-balance-sheet arrangements. Management stated disclosure controls were effective as of March 31, 2016 and reported no material changes in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether revenue and tender-market share stabilize, particularly for Cefaclor and other major products.
- Whether aged receivables are collected and whether the allowance remains adequate; reconcile the aging disclosures with the balance-sheet net receivable amount.
- Availability of cash for corporate needs given PRC remittance restrictions, and the company’s ability to meet 2016 short-term debt maturities and construction-loan payments.
- Whether CFDA approvals and consistency-evaluation requirements delay pipeline commercialization or trigger further formula commitments.
- Whether operating cash flow is sustainable and management’s 12-month liquidity assumptions remain achievable despite ongoing losses and pricing pressure.